THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On December27, 2017, Ms.Henrietta H. Fore notified Theravance Biopharma,Inc. (the “Company”) of her resignation as Director of the Company effective on December31, 2017. Ms.Fore indicated her resignation was in connection with her appointment as Executive Director of the United Nations Children’s Fund (UNICEF) effective January1, 2018 and not as the result of any disagreement with the Board or with the Company’s management. The Company thanks Ms.Fore for her service as a Director of the Company and wishes her well in her new position.
About THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
An ad to help with our costs